Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Introduction to Innate and Adaptive Immunity01:21

Introduction to Innate and Adaptive Immunity

The human immune system is a complex defense mechanism that protects the body from harmful pathogens and foreign substances. It comprises two crucial components: innate and adaptive immunity.
Innate immunity is the body's natural, nonspecific defense system that acts quickly to protect against pathogens. It incorporates physical barriers like skin and mucous membranes and cellular elements such as phagocytes and natural killer cells. This part of our immune system provides an immediate,...
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health status of living kidney donors and attitude toward donation-Results from the German Living Donor Registry (SOLKID-GNR).

Frontiers in medicine·2026
Same author

Pathogen-specific epidemiology and clinical trajectories of fungal infections after kidney transplantation: a prospective multicenter cohort study.

BMC infectious diseases·2026
Same author

Long-Term Outcomes Across Age and Risk Profiles in a Caucasian Living Kidney Donor Cohort.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Age-Related Risk After Kidney Transplantation: A Comprehensive Analysis of Infection Burden, Graft Outcomes, and Mortality.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

[Polypharmacy and nephrotoxicity].

Innere Medizin (Heidelberg, Germany)·2026
Same author

Self-Reported Outcome of Living Kidney Donation Correlates With Perioperative Complications not With Surgical Techniques.

Kidney international reports·2025
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Approaches towards individualized immune intervention.

Thomas Giese1, Claudia Sommerer, Martin Zeier

  • 1Department of Immunology, University of Heidelberg, Heidelberg, Germany. giese@uni-hd.de

Digestive Diseases (Basel, Switzerland)
|May 13, 2010
PubMed
Summary
This summary is machine-generated.

Long-term immunosuppression increases cancer risk in transplant patients. A new test correlates immunosuppression levels with malignancy, enabling personalized treatment to prevent cancer and infections while preserving organ function.

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
18:08

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: December 31, 2007

Related Experiment Videos

Last Updated: Jun 13, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation
18:08

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: December 31, 2007

Area of Science:

  • Transplantation Medicine
  • Immunology
  • Oncology

Background:

  • Long-term immunosuppression in transplant recipients elevates malignancy risk.
  • Immunosuppression impairs anti-tumor surveillance and antiviral immune responses.
  • Previous understanding of this link was largely qualitative.

Purpose of the Study:

  • To investigate the correlation between individual immunosuppression levels and malignancy incidence in kidney transplant patients.
  • To validate a pharmacodynamic assay for assessing immune cell function.
  • To explore the potential for individualized immunosuppressive therapy.

Main Methods:

  • Utilized a novel pharmacodynamic assay to quantify immune cell activity.
  • Analyzed data from kidney transplant patients treated with cyclosporin A.
  • Correlated assay results with the incidence of malignancies.

Main Results:

  • A strong correlation was observed between the degree of immunosuppression and malignancy development.
  • The pharmacodynamic assay effectively measured individual immunosuppression levels.
  • This highlights the potential for personalized immunosuppressive drug dosing.

Conclusions:

  • A quantitative assessment of immunosuppression is crucial for managing transplant patients.
  • Individualized immunosuppressive therapy can mitigate cancer and infection risks.
  • This approach represents a significant advancement in transplantation medicine.